Evaluating the NutriSteppe Digital Diet App for Adults Aged 21 to 65 with Type 2 Diabetes, Obesity, or Overweight Using GLP-1 Receptor Agonist Therapy

What this Trial Is About

Researchers are evaluating whether adding the NutriSteppe digital dietary intervention to routine medical care improves metabolic health in adults aged 21 to 65 years who have type 2 diabetes, obesity, or are overweight with related health issues. Participants in this study are already receiving or have been prescribed glucagon-like peptide-1 GLP-1 receptor agonist therapy by their doctors outside of this trial. The main goal is to see if the NutriSteppe app improves glycated hemoglobin HbA1c, a measure of average blood glucose, after 12 weeks compared to routine care alone. Participants are randomly assigned to one of two groups. Both groups continue their routine medical care including GLP-1 receptor agonist therapy. The control group receives general lifestyle advice, while the intervention group uses the NutriSteppe mobile app, which provides personalized meal planning, food diaries, nutritional analysis, educational modules, reminders, and dietary recommendations for 12 weeks. All participants photograph their food and drink, and these photos are analyzed by an automated system called Tagam-AI. Only the intervention group receives personalized dietary advice based on this analysis. During the study, participants attend visits for examinations, laboratory tests, and questionnaires. Researchers measure changes in HbA1c, fasting glucose, body weight, body mass index, waist circumference, cholesterol levels, blood pressure, diet quality, quality of life, and dietary adherence. Safety is monitored by tracking adverse events and laboratory parameters. Participants use the NutriSteppe app at least five days per week and record body weight weekly. The total participation lasts 12 weeks with regular assessments throughout.

Digital Dietary Intervention for Patients Receiving GLP-1 Receptor Agonist Therapy